Table 3 MMR at 12 months (primary end... | American Society of Hematology

Table 3

MMR at 12 months (primary end point)

	Nilotinib	Imatinib	Nilotinib vs imatinib response rate difference, % (95% CI)*
Overall	134	133	—
Patients with response	70 (52.2)	37 (27.8)	24.4 (13.0-35.8)
P vs imatinib	<.0001		—
Low Sokal risk†	69	69	—
Patients with response‡	44 (63.8)	22 (31.9)	31.9 (16.1-47.7)
Intermediate Sokal risk†	44	43	—
Patients with response‡	18 (40.9)	13 (30.2)	10.7 (9.3-30.7)
High Sokal risk†	21	21	—
Patients with response‡	8 (38.1)	2 (9.5)	28.6 (4.3-52.8)
No prior rIFNɑ†	123	122	—
Patients with response‡	64 (52.0)	33 (27.0)	25.0 (13.1-36.8)
Prior rIFNɑ†	11	11	—
Patients with response‡	6 (54.5)	4 (36.4)	18.2 (−22.7-59.1)

	Nilotinib	Imatinib	Nilotinib vs imatinib response rate difference, % (95% CI)*
Overall	134	133	—
Patients with response	70 (52.2)	37 (27.8)	24.4 (13.0-35.8)
P vs imatinib	<.0001		—
Low Sokal risk†	69	69	—
Patients with response‡	44 (63.8)	22 (31.9)	31.9 (16.1-47.7)
Intermediate Sokal risk†	44	43	—
Patients with response‡	18 (40.9)	13 (30.2)	10.7 (9.3-30.7)
High Sokal risk†	21	21	—
Patients with response‡	8 (38.1)	2 (9.5)	28.6 (4.3-52.8)
No prior rIFNɑ†	123	122	—
Patients with response‡	64 (52.0)	33 (27.0)	25.0 (13.1-36.8)
Prior rIFNɑ†	11	11	—
Patients with response‡	6 (54.5)	4 (36.4)	18.2 (−22.7-59.1)

Values are n or n (%) unless otherwise indicated.

95% CIs for the differences in MMR rates between treatment groups calculated using the Wald method.

Total number of patients in each subgroup.

Frequency of MMR at 12 months among patients in each subgroup.